.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC18_Triflusal.Triflusal

Information

Triflusal is an antiplatelet agent derived from salicylic acid, used to prevent thromboembolic events in patients at risk of stroke or myocardial infarction, particularly in those with intolerance to acetylsalicylic acid. It acts mainly by inhibiting platelet aggregation. Although once widely used in several countries, it is currently not approved in the United States or many other regions.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), age range 18–64 years.

References

1. Park, SM, et al., & Han, S (2014). Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. BMC pharmacology & toxicology 15 75–None. DOI:10.1186/2050-6511-15-75 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25534747

2. Lee, HW, et al., & Yoon, YR (2011). A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert opinion on drug metabolism & toxicology 7(12) 1471–1479. DOI:10.1517/17425255.2011.630661 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22098139

3. Wang, M, et al., & Zhou, W (2014). Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Drug research 64(5) 263–268. DOI:10.1055/s-0033-1357180 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24105106

Revisions

• 06/2025 initial generated model